News Search Results
Aug 06, 2025, 08:05 ET Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets
unmet medical needs using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for central nervous system ("CNS") disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ("COPD") and allergic bronchopulmonary aspergillosis
More news about: Pulmatrix Inc.
Aug 06, 2025, 07:02 ET The U.S. FDA Granted Fast Track Designation to Dizal's Birelentinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
growth of B-NHLs in cell lines and in animal models. In clinical studies, birelentinib exhibits favorable PK properties, good central nervous system (CNS) permeability, complete blockade of BCR signaling, and encouraging anti-tumor efficacy with good safety and tolerability in patients with B-NHL.
More news about: Dizal Pharmaceutical
Aug 05, 2025, 16:01 ET Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update
its opt-in right related to the development and commercialization of ocadusertib (previously R552) for the treatment of non-central nervous system (CNS) diseases. As a result of the notification, Rigel recognized $40.0 million in non-cash revenue resulting from the release
More news about: Rigel Pharmaceuticals, Inc.
Aug 05, 2025, 08:00 ET Curis Provides Second Quarter 2025 Business Update
Analysis of genetic mutation profile and CNS pharmacokinetics in relapsed/refractory primary CNS lymphoma patients responding to novel emavusertib (IRAK4i) and BTKi combination.Continued to enroll relapsed/refractory
More news about: Curis, Inc.
Aug 03, 2025, 08:25 ET ANRO Investors Have the Opportunity to Lead the Alto Neuroscience Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
$17 from $33 and stated that ALTO-100's data raises questions around the Company's overall biomarker approach to CNS disorders and psychiatry. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class
More news about: Faruqi & Faruqi, LLP
Jul 31, 2025, 16:19 ET Cohen & Steers, Inc. Declares Quarterly Dividend
July 31, 2025 /PRNewswire/ -- The Board of Directors of Cohen & Steers, Inc. (NYSE: CNS) declared a cash dividend for the third quarter of 2025 in the amount of $0.62 per share of common stock payable on
More news about: Cohen & Steers, Inc.
Jul 31, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO
a pro-neurogenesis/neuroplasticity mechanism of action" and has stated that the Company "believe[s] binds a receptor not targeted by other [central nervous system ("CNS")] therapeutics, which would make it first-in-class if approved." On January 12, 2024, Alto filed a registration
More news about: Pomerantz LLP
Jul 31, 2025, 07:00 ET Corero Network Security Partners with Beyond Technology MEA to Expand DDoS Protection in Pakistan
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service (DDoS) protection specialists, announced a strategic partnership with
More news about: Corero Network Security
Jul 30, 2025, 17:55 ET Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Jul 30, 2025, 17:51 ET Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com/Symbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Jul 30, 2025, 17:48 ET Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Jul 30, 2025, 17:44 ET Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com/Symbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Jul 30, 2025, 17:43 ET Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Jul 30, 2025, 10:10 ET EuMentis Therapeutics Receives U.S. FDA Clearance of IND Application for EM-221, a Novel PDE10A Inhibitor for Schizophrenia
advancing novel treatments for schizophrenia and other central nervous system (CNS) conditions. EuMentis is committed to leading innovation in the neuropsychiatric disease field by advancing programs that target selective CNS circuits in the brain with clinically validated mechanisms of action. This approach
More news about: EuMentis Therapeutics, Inc.
Jul 30, 2025, 09:46 ET Alamar Biosciences spolupracuje s Německým centrem pro neurodegenerativní onemocnění (DZNE) na průlomovém proteomickém profilování v kohortě Studie Porýní
života. Nasazení panelu NULISAseq CNS Disease Panel 120 od společnosti Alamar výzkumníkům umožní stanovovat hladiny stovek proteinů s významem pro fungování mozku z minimálního objemu krve s výjimečnou citlivostí a specificitou. Pozoruhodná je zejména schopnost panelu CNS rozlišit fosforylovaný tau protein
More news about: Alamar Biosciences, Inc.
Jul 30, 2025, 09:27 ET Alamar BiosciencesとGerman Center for Neurodegenerative Diseases（DZNE）、ラインラント研究（Rhineland Study）コホートにおける画期的なプロテオミクス・プロファイリング研究で提携
NULISAseq™ CNS Disease Panel 120とInflammation Panel 250で、23,000件の縦断的検体におけるバイオマーカー発見を推進 カリフォルニア州フリーモント、2025年7月30日 /PRNewswire/ -- 精密プロテオミクス技術を活用し、疾患の早期発見を可能にするAlamar Biosciencesは本日、German Center for Neurodegenerative Diseases（DZNE）との戦略的提携を発表しました。この提携により、同社の超高感度NULISAseq™
More news about: Alamar Biosciences, Inc.
Jul 30, 2025, 09:01 ET Alamar Biosciences и Немецкий центр нейродегенеративных заболеваний (DZNE) совместно проводят знаковое исследование по протеотомному профилированию в когортном исследовании Rhineland Study
протяжении всей жизни. Используя панель NULISAseq CNS Disease Panel 120 от Alamar, исследователи смогут определять сотни белков, связанных с работой мозга, в минимальных объемах крови с исключительной чувствительностью и специфичностью. Так, способность панели CNS отличать фосфорилированный тау-белок из тканей
More news about: Alamar Biosciences, Inc.
Jul 30, 2025, 08:57 ET Alamar Biosciences dan German Center for Neurodegenerative Diseases (DZNE) bermitra untuk penelitian Landmark Proteomic Profiling dalam Kelompok Rhineland Study
sepanjang rentang kehidupan. Dengan menggunakan NULISAseq CNS Disease Panel 120 Alamar, peneliti akan dapat mengukur ratusan protein terkait otak dari volume darah yang minimal dengan sensitivitas dan kekhususan yang luar biasa. Khususnya kemampuan panel CNS dalam membedakan antara tau terfosforilasi yang berasal
More news about: Alamar Biosciences, Inc.
Jul 29, 2025, 22:09 ET Alamar Biosciences et le Centre allemand pour les maladies neurodégénératives (DZNE) s'associent pour une étude historique de profilage protéomique dans la cohorte d'étude rhénane
utilisant le NULISAseq CNS Disease Panel 120 d'Alamar, les chercheurs seront capables de mesurer des centaines de protéines liées au cerveau à partir de volumes sanguins minimes, avec une sensibilité et une spécificité exceptionnelles. En particulier, la capacité du panel CNS à distinguer la protéine
More news about: Alamar Biosciences, Inc.
Jul 29, 2025, 15:20 ET Alamar Biosciences und das Deutsche Zentrum für Neurodegenerative Erkrankungen (DZNE) arbeiten an wegweisender Proteomic-Profiling-Studie in Kohorte der Rheinland-Studie zusammen
NULISAseq™ CNS Disease Panel 120 und Inflammation Panel 250 unterstützen die Entdeckung von Biomarkern in 23.000 Längsschnittproben FREMONT, Kalifornien, 29. Juli 2025 /PRNewswire/ -- Alamar Biosciences, ein
More news about: Alamar Biosciences, Inc.
Jul 29, 2025, 14:43 ET Spoločnosť Alamar Biosciences a Nemecké centrum pre neurodegeneratívne ochorenia (DZNE) spolupracujú na štúdii pre významné proteomické profilovanie v kohorte štúdie Porýnia
celého života. Vďaka využitiu panela ochorení CNS NULISAseq 120 od spoločnosti Alamar budú vedci schopní merať stovky proteínov súvisiacich s mozgom z minimálneho objemu krvi s výnimočnou citlivosťou a špecifickosťou. Je pozoruhodné, že schopnosť panela CNS rozlíšiť fosforylovaný tau proteín odvodený z
More news about: Alamar Biosciences, Inc.
Jul 29, 2025, 11:50 ET Alamar Biosciences 與德國神經退化性疾病中心 (DZNE) 合作，在萊茵蘭研究群體中進行具里程碑意義的蛋白質體學分析研究
NULISAseq™ CNS Disease Panel 120 和 Inflammation Panel 250 在 23,000 個縱向樣本中，推動生物標記發現 加州佛利蒙2025年7月29日 /美通社/ -- Alamar Biosciences 是驅動精準蛋白質組學研究而實現最早期檢測疾病的公司，今天宣佈與德國神經退化性疾病中心 (DZNE) 建立策略合作關係，而於萊茵蘭研究部署超靈敏的 NULISAseq™ CNS Disease
More news about: Alamar Biosciences, Inc.
Jul 29, 2025, 11:34 ET Alamar Biosciences i Niemiecki Ośrodek Chorób Neurodegeneracyjnych (DZNE) rozpoczynają współpracę nad przełomowym badaniem proteomicznym w kohorcie badania Rhineland
związanych z pracą mózgu, począwszy od ich minimalnej zawartości we krwi, z wyjątkową czułością i szczegółowością. Możliwość rozróżnienia za pomocą panelu CNS fosforylowanego białka tau pochodzenia mózgowego od całkowitego fosforylowanego białka tau w osoczu stanowi przełomowy krok w kierunku wczesnego wykrywania
More news about: Alamar Biosciences, Inc.
Jul 29, 2025, 10:28 ET INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
$17 from $33 and stated that ALTO-100's data raises questions around the Company's overall biomarker approach to CNS disorders and psychiatry. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class
More news about: Faruqi & Faruqi, LLP
Jul 29, 2025, 09:12 ET 알라마 바이오사이언스, 독일 신경퇴행성질환센터(DZNE)와 파트너십 체결 - 라인란트 연구 코호트에서 대규모 단백질체 분석 연구 착수
DZNE 라인란트 연구는 건강한 노화의 결정 요인과 전 생애에 걸친 신경퇴행성 질환 발병의 결정 요인을 조사하기 위해 고안된 대규모 인구 기반 코호트 연구다. 연구자들은 알라마의 NULISAseq CNS 질환 패널 120을 활용하여 최소한의 혈액량으로 수백 개의 뇌 관련 단백질을 높은 민감도와 특이도로 측정할 수 있게 된다. 특히, CNS 패널이 혈장에서 뇌 유래 인산화 타우와 총 인산화 타우를 구별해 측정할 수 있어, 알츠하이머병과 같은 신경퇴행성 질환의 조기 진단 및 위험도 분류에 있어 획기적인 진전을 이룰 것으로 기대한다. 또한,
More news about: Alamar Biosciences, Inc.